Till now we have a specific anticancer drug for each type of cancer but a new drug "Larotrectinib: works on Gene of multiple cancers of adult and paediatric group, in children it is affecting 93% of cancers. If larotrectinib receives approval from the U.S. Food and Drug Administration, it will represent the first time a drug is initially approved because it targets a specific molecular change independent of tumor type.
Larotrectinib’s maker, Loxo Oncology, is also one of the first to develop a cancer drug, almost in parallel, in adults and children. The division chief of Hematology and Oncology at Seattle Children’s, remembers matching one of the first pediatric cancer patients to an experimental drug that targets a specific set of genetic alterations associated with soft tissue tumors. The drug, Larotrectinib, is designed to selectively stop the resulting abnormal tropomyosin receptor…
